Ginkgo Bioworks Adopts Inscripta’s Onyx Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput
January 10 2022 - 8:00AM
Business Wire
Inscripta, the digital genome engineering company, today
announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal
platform for cell programming, has adopted the Onyx™ genome
engineering platform in its foundries. Ginkgo’s investment is part
of its commitment to integrating cutting-edge technology into its
foundries as it aims to increase the performance and productivity
of its metabolic and protein engineering workflow and grow its
pipeline.
“Ginkgo is driving towards an impressive vision of how synthetic
biology can enable new applications across many diverse industries
from food and agriculture to industrial chemicals to
pharmaceuticals. We believe Inscripta’s Onyx platform can be a
powerful addition to the future foundry capabilities that Ginkgo is
building,” said Sri Kosaraju, President and CEO of Inscripta.
“Ginkgo is another notable early partner of ours who is moving
quickly and showing significantly improved results and increased
performance in their genome engineering efforts with the Onyx
platform.”
In an initial evaluation, Ginkgo reported that the Onyx platform
demonstrated an order of magnitude increase in the throughput of
certain genome editing capabilities for S. cerevisiae and E. coli,
which led to a significant increase in strain performance as
measured by the production of a target metabolite. Additionally,
with the Onyx integration, Ginkgo scientists reported in the
initial evaluation that their platform delivered faster turnaround
times and reduced the design-build-test-learn cycle time by at
least 50 percent, which could enable faster product
development.
"We plan to continue making investments in innovative
technologies such as the Onyx platform so that customers can start
their product development process within our foundries and leverage
our high throughput screening,” said Barry Canton, Chief Technology
Officer of Ginkgo Bioworks. “Our commitment is to continue
capitalizing on the diverse technology, resources, and expertise
within Ginkgo’s network of suppliers — exemplified by Inscripta —
as we aim to provide our partners with access to the newest
specialized technology as the industry innovates.”
Jason Kelly, co-founder and CEO of Ginkgo Bioworks and Sri
Kosaraju will participate in a synthetic biology panel at the 40th
annual JP Morgan Healthcare Conference. The panel, which takes
place at the virtual event on Monday, January 10 at 5:15 p.m. EST,
also includes leaders from the White House Office of Science and
Technology as well as International Flavors & Fragrances Inc.
and is being moderated by JP Morgan analyst Tycho Peterson and
Ipsita Smolinski of Capitol Street. The panel will be broadcast
live and available for on-demand viewing at:
https://jpmorgan.metameetings.net/events/healthcare22/sessions/40447-panel-synthetic-biology/webcast?gpu_only=true&kiosk=true.
About Inscripta
Inscripta is a life science technology company enabling
scientists to solve some of today's most pressing challenges with
the first benchtop system for genome editing. The company's
automated Onyx platform, consisting of an instrument, consumables,
assays, and software, makes CRISPR-based genome engineering
accessible to any research lab. Inscripta supports its customers
around the world from facilities in Boulder, Colorado; San Diego
and Pleasanton, California; and Copenhagen, Denmark. To learn more,
visit Inscripta.com and follow @InscriptaInc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005348/en/
Tim Ingersoll tim@bioscribe.com 619-871-3769
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ginkgo Bioworks (NYSE:DNA)
Historical Stock Chart
From Apr 2023 to Apr 2024